Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359–362. 10.1126/science.2523562
Article
CAS
PubMed
Google Scholar
Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000, 90(10):1562–1569.
Article
PubMed Central
CAS
PubMed
Google Scholar
Veldt BJ, Heathcote EJ, Wedemeyer H, et al.: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147(10):677–684. 10.7326/0003-4819-147-10-200711200-00003
Article
PubMed
Google Scholar
Brazilian Ministry of Health: Relatório técnico do estudo de prevalência de base populacional das infecções pelos vírus das hepatites A, B e C nas capitais do Brasil: dados preliminares. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Recife, Brazil. Ministry of Health, 2010 Feb in: Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Brasilia, Brazil. Ministry of Health, June 2011
Brazilian Ministry of Health: Boletim epidemiológico: hepatites virais. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Brazilia, Brazil. Ministry of Health, 2010 in: Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Brasilia, Brazil. Ministry of Health, June 2011
Brazilian Ministry of Health News: Ministério amplia acesso a medicamento para hepatite C. 2011.
Google Scholar
Brazilian Ministry of Health: Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis, Brasilia, Brazil. Ministry of Health, June 2011
Awad T, Thorlund K, Hauser G, et al.: Peginterferon alfa-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010, 51(4):1176–1184. 10.1002/hep.23504
Article
CAS
PubMed
Google Scholar
Alavian SM, Behnava B, Tabatabaei SV: The comparative efficacy and safety of peginterferon alfa-2s vs. 2b for the treatment of chronic HCV infection: A meta-analysis. Hepat Mon 2010, 10(2):121–131.
PubMed Central
PubMed
Google Scholar
Zhao S, Liu E, Chen P, et al.: A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Clin Ther 2010, 32(9):1565–77. 10.1016/j.clinthera.2010.08.009
Article
CAS
PubMed
Google Scholar
Nan Xiao N, Shi S, Zhuang H: A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection. Hepatic Medicine: Evidence and Research 2010, 2: 99–109.
Article
Google Scholar
Singal AK, Jampana SC, Anand BS: Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci 2011, 56(8):2221–6. 10.1007/s10620-011-1765-0
Article
CAS
PubMed
Google Scholar
Cheinquer H, Barros FMR, Borges LG, et al.: Systematic review and meta-analysis of published randomized controlled trials comparing the efficacy of peginterferon-alpha-2a versus peginterferon alpha-2b both plus ribavirin in chronic hepatitis C patients. Value in Health 2010, 13(no. 3):A69.
Article
Google Scholar
Mar J, et al.: Cost-effectiveness analysis of pegylated interferons combined with ribavirin in the treatment of hepatitis C. Value in Health 2003, 6(6):759.
Article
Google Scholar
Orlewska E: The cost-effectiveness analysis of combination of peginterferon alfa-2a and ribavirin versus combination of peginterferon alfa-2b and ribavirin in chronic hepatitis in Poland. Value in Health 2004, 7(3):356.
Article
Google Scholar
Klaskala W, et al.: Cost-effectiveness modeling of treatment approaches to hepatitis C: a managed care perspective. Value in Health 2004, 7(3):355–356.
Article
Google Scholar
Latimer NR, Lewis GJ: A cost-utility analysis of peginterferon alfa-2a (40kD) versus peginterferon alfa-2b (12kD) for the treatment of chronic hepatitis C (CHC) in the UK. Value in Health 2005, 8(6):A58.
Article
Google Scholar
Lewis GJ, et al.: A comparison of cost-effectiveness of pginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (Copegus) versus interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C in the UK. Value in Health 2004, 7(6):763–764.
Article
Google Scholar
Escudero GS, Idrovo J, Rivas R, Rodriguez JR, Alba IAR, Zapata L, et al.: Cost-effectiveness of peg-IFN alfa 2a or 2b plus ribavirin in the treatment of chronic hepatitis C in Mexico. Value in Health 2009, 12(3):A59.
Article
Google Scholar
Ventayol-Bosch P, et al.: Cost-effectiveness analysis of treatment of chronic hepatitis C patients with peginterferon alfa-2a or peginterferon alfa-2b both plus ribavirin in Spain. Value in Health 2010, 13(7):A438.
Article
Google Scholar
Vianna CMM, Caetano R: Diretrizes Metodológicas para Estudos de Avaliação Econômica de Tecnologias para o Ministério da Saúde. 2009.
Google Scholar
Tatsch FF, Sette Júnior H, Vianna D: Pharmacoeconomics applied to chronic hepatitis C. Braz J Infect Dis 2006, 10(1):51–54. 10.1590/S1413-86702006000100010
Article
PubMed
Google Scholar
Paraná R, Sette H, Pessoa M, Bueno RLP, et al.: Custo-efetividade de peginterferon alfa-2a (40 KD) associado a ribavirina no tratamento de pacientes com hepatite crônica C genótipos 2 e 3. 2006.
Google Scholar
Sullivan SD, Green J, Patel KK, et al.: Comparison of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) versus interferon alfa-2b plus ribavirin in chronic hepatitis C. Value in Health 2003, 6(3):262.
Article
Google Scholar
Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al.: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23: 1334–1340. 10.1002/hep.510230607
Article
CAS
PubMed
Google Scholar
Kim WR, Poterucha JJ, Hermans JE, Therneau TM, et al.: Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997, 127: 866–874. 10.7326/0003-4819-127-10-199711150-00002
Article
CAS
PubMed
Google Scholar
Fattovich G, Giustina G, Degos F: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997, 112(2):463–72. 10.1053/gast.1997.v112.pm9024300
Article
CAS
PubMed
Google Scholar
Gines P, Quintero E, Arroyo V, et al.: Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7(no. 1):122–128. 10.1002/hep.1840070124
Article
CAS
PubMed
Google Scholar
Tsukuma H, Hiyama T, Tanaka S, et al.: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328(25):1797–801. 10.1056/NEJM199306243282501
Article
CAS
PubMed
Google Scholar
Colombo M, de Franchis R, Del Ninno E, Sangiovanni , et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 328: 64–65.
Google Scholar
Bennett WG, Inoue Y, Beck JR, et al.: Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997, 127: 918–920. 10.7326/0003-4819-127-10-199711150-00011
Article
Google Scholar
Ascher NL, Lake JR, Emond J, et al.: Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994, 20: 245–275. 10.1016/S0168-8278(05)80065-0
Article
Google Scholar
Detre KM, Belle SH, Lombardero M: Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996, 2: 219–228.
Google Scholar
Kilpe VE, Krakauer H, Wren RE: An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993, 56: 554–561. 10.1097/00007890-199309000-00012
Article
CAS
PubMed
Google Scholar
Brazilian Geography and Statistics Institute – IBGE Available from: home http://www.ibge.gov.br/
Younossi Z, McCormick M, Boparai N, et al.: Impact of chronic liver disease on patients' utilities [Abstract]. Gastroenterology 1999, 116: A1292.
Google Scholar
Brazilian Ministry of Health: Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS - SIGTAP. Available from sigtap.datasus.gov.br/. Accessed Nov 2009
Brazilian Official Gazette Section 3. n 129, July 7th 2011
Brazilian Official Gazette Section 3. n 121, June 27th 2011
Brazilian Official Gazette Section 3. n 122, June 28th 2011
Ascione A, De Luca M, Tartaglione MT, et al.: Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010, 138(no. 1):116–22. Epub 2009 Oct 20 10.1053/j.gastro.2009.10.005
Article
CAS
PubMed
Google Scholar
Rumi MG, Aghemo A, Prati GM, et al.: Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138(no. 1):108–15. Epub 2009 Sep 18 10.1053/j.gastro.2009.08.071
Article
CAS
PubMed
Google Scholar
McHutchison JG, Lawitz EJ, Shiffman ML, et al.: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361(6):580–93. 10.1056/NEJMoa0808010
Article
CAS
PubMed
Google Scholar
Yenice N, Mehtap O, Gumrah M, et al.: The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006, 17(2):94–98.
PubMed
Google Scholar
Scotto G, Fazio V, Fornabaio C, Tartaglia A, et al.: Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008, 28(10):623–9. 10.1089/jir.2007.0116
Article
CAS
PubMed
Google Scholar
Berak H, Kolakowska-Rzadzka A, Wasilewski M, et al.: Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2b vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes - final analysis. Journal of Hepatology 2007, 46: S217-S218.
Article
Google Scholar
Kolakowska A, Berak H, Wasilewski M, et al.: Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology 2008, 48(no. 4):878A.
Google Scholar